Table 1 In- and exclusion criteria of the INKA study
From: Ion therapy within the trimodal management of superior sulcus tumors: the INKA trial
Inclusion Criteria | |
Patients meeting all of the following criteria will be considered for admission to the trial: | |
• | histological confirmed superior sulcus tumor (NSCLC) |
• | maximal stage N2 in a FDG-PET-CT |
• | age between 18 and 75 years |
• | Karnofsky Performance Score ≥70 |
• | Written informed consent (must be available before enrolment in the trial) |
Exclusion Criteria | |
Patients presenting with any of the following criteria will not be included in the trial: | |
• | refusal of the patients to take part in the study |
• | medical contraindications against one of the parts in the trimodal concept |
• | stage N3 disease in FDG-PET-CT |
• | stage IV disease |
• | previous radiotherapy to the thoracic region |
• | Participation in another clinical study or observation period of competing trials, respectively |
• | no capacity to consent |
• | active medical devices, for which no approval for ion-therapy exists (i.e. cardiac pacemaker, defibrillator, …) |
• | decompensated diseases of the lungs, cardio-pulmonal system, metabolism, hematopoetic system, coagulation system or renal function |